3,281 results found
    1. Chromosomes and Gene Expression

    Dominant drug targets suppress the emergence of antiviral resistance

    Elizabeth J Tanner et al.
    When antiviral compounds target oligomeric assemblages, the formation of chimeric oligomers within cells can negate selection for naturally occurring drug-resistant variants.
    1. Cell Biology
    2. Computational and Systems Biology

    Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells

    Anil Korkut et al.
    Data-driven systems biology models of signaling predict cellular response to untested perturbations and can nominate drug combinations to overcome drug resistance in cancer cells.
    1. Computational and Systems Biology
    2. Microbiology and Infectious Disease

    Modeling the metabolic interplay between a parasitic worm and its bacterial endosymbiont allows the identification of novel drug targets

    David M Curran et al.
    A genome scale model of Brugia malayi metabolism illustrates a dynamic reliance on energy production pathways across its life cycle and identifies new drugs with experimentally supported anti-parasitic properties.
    1. Cancer Biology

    BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling

    Harina Vin et al.
    The cancer drug vemurafenib has potent off-target effects on JNK signaling that contribute to the development of squamous cell carcinomas in humans and in mice.
    1. Cancer Biology

    CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials

    Ann Lin et al.
    A putative therapeutic target undergoing clinical trials in breast cancer is non-essential and the drug used in those trials blocks cell division through an off-target effect.
    1. Evolutionary Biology
    2. Cancer Biology

    Evolutionary dynamics of cancer in response to targeted combination therapy

    Ivana Bozic et al.
    A study that models the evolution of drug resistance in tumors reveals that drugs are more effective when given in combination than sequentially, and that cure is much more likely when the drugs target different pathways.
    1. Cancer Biology
    2. Immunology and Inflammation

    A perspective on HPK1 as a novel immuno-oncology drug target

    Sansana Sawasdikosol, Steven Burakoff
    HPK1 is an important immuno-oncology drug target that may induce superior anti-tumor immunity through the multiple roles HPK1 may play at multiple steps of the cancer immunity cycle.
    1. Cell Biology
    2. Cancer Biology

    Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer

    Keren Yizhak et al.
    Genome-scale metabolic modeling of individual cancer cells and healthy human cells identifies specific and selective metabolic vulnerabilities.
    1. Immunology and Inflammation

    Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo

    Dana E Orange et al.
    By using immune cells called dendritic cells to deliver drugs, it is possible to target and kill specific members of another class of immune cell, known as T cells, and to prevent these cells from attacking the body's own tissues in cases of autoimmune disease.
    1. Cancer Biology
    2. Structural Biology and Molecular Biophysics

    Dynamics of human protein kinase Aurora A linked to drug selectivity

    Warintra Pitsawong et al.
    Slow conformational changes after drug binding rationalize selectivity, affinity and long on-target residence time for kinase inhibitors.

Refine your results by:

Type
Research categories